Healthy
Conditions
Keywords
Prednisolone acetate, eye drops, tolerability, Healthy volunteers
Brief summary
The objective of this trial was to confirm the tolerability of prednisolone acetate 0.5% eye drops by testing the hypothesis that the ocular safety and tolerability of prednisolone acetate 0.5% eye drops are equivalent to vehicle. Thus healthy volunteers have been selected and have been treated by using a crossover design.
Interventions
DRUGPrednisolone acetate
Sponsors
Novartis
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Healthy subjects of either gender, 18 years or older, who were able to give an informed consent * A score for ocular discomfort of 0-20 mm on the visual analogue scale (VAS) prior to treatment
Exclusion criteria
* Known hypersensitivity to any of the constituents of the medications * Known corticosteroid responder (elevation of intraocular pressure \[IOP\]) * Known allergic disposition (e.g. hay fever) * Need of ocular antiallergic treatment * Wearing of contact lenses * Any kind of current eye disease (e.g. dry eye) * Any kind of concomitant ocular treatment * Any injury or infection in either eye during the last 3 months prior to the first application * Any medication taken within the last 28 days prior to the first application, except hormonal contraceptives * Concomitant or previous treatment with antihistamines within a week prior to enrolment * Pregnant or breast feeding women * Participation in another clinical study within 4 weeks prior to enrolment * Hematological diseases such as aplastic anemia, panmyelopathy, or hemolytic icterus; with severe dysfunction of the liver. * Any medical or laboratory condition which, in the Investigator's opinion, would preclude the participant from adhering to the protocol or completing the trial per protocol * Subjects with history of malignancy of any organ system, treated or untreated, within the past five years, whether or not evidence of local recurrence or metastases exist, are excluded, with the exception of localized basal cell carcinoma of the skin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tolerability of the trial drug by evaluating the overall sum-score of the slit lamp examination built by adding up the scores for conjunctival hyperemia, conjunctival edema, palpebral hyperemia, lid edema and corneal edema | — |
Secondary
| Measure | Time frame |
|---|---|
| Tolerability of the trial drug | — |
| and the frequency, severity and relationship to study medication of all adverse events occurring during the course of the study. | — |
Countries
Germany
Outcome results
None listed